AC
ASBP

Antara Capital’s Aspire Biopharma ASBP Stock Holding History

Antara Capital’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$26.8K Hold
169
– – 88.65% 1
2025
Q3 		$41.8K Buy
+169
New +$84.6K 8.53% 2

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
RA
Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return
TSW
Three Seasons Wealth Salt Lake City, Utah $1.1B AUM 50.99% 1-Year Est. Return

Antara Capital's ASBP Position: Q4 2025 in Review

Antara Capital held its Aspire Biopharma (ASBP) position steady in Q4 2025 at 169 shares worth $26.8K. The position accounts for 88.65% of the portfolio, ranked #1.

Antara Capital first reported a position in ASBP in Q3 2025 and has held it in 2 quarters since. The position peaked at $41.8K in Q3 2025. 28 funds tracked by Wall St. Rank hold ASBP as of Q4 2025.

  • Antara Capital held 169 shares of Aspire Biopharma worth $26.8K as of Q4 2025.
  • Antara Capital left its Aspire Biopharma share count unchanged in Q4 2025.
  • Aspire Biopharma made up 88.65% of Antara Capital's portfolio in Q4 2025, its #1 holding.
  • Antara Capital first reported a position in Aspire Biopharma in Q3 2025 and has held it in 2 quarters since.
  • Antara Capital's Aspire Biopharma position peaked at $41.8K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2025.

Based on Antara Capital's 13F filing for Q4 2025, filed 17 Feb 2026.